Buss A, Brook G A, Kakulas B, Martin D, Franzen R, Schoenen J, Noth J, Schmitt A B
Department of Neurology, Aachen University Hospital, Pauwelsstrasse 30, 52074 Aachen, Germany.
Brain. 2004 Jan;127(Pt 1):34-44. doi: 10.1093/brain/awh001. Epub 2003 Oct 8.
Axons undergo Wallerian degeneration distal to a point of injury. Experimental investigations have documented many of the cellular and molecular events that underlie this behaviour. Since relatively little is known about such events in human CNS pathologies and current experimental intervention strategies indicate the possibility of significant axon regeneration along the original degenerated fibre tract, we performed an immunohistochemical investigation of the dynamics of Wallerian degeneration in post mortem spinal cords of patients who died 2 days to 30 years after either cerebral infarction or traumatic spinal cord injury. Neurofilament (NF) staining demonstrated a spatio-temporal pattern of axonal loss within degenerating descending nerve fibre tracts that could be detected close to the lesion as early as 12 days after injury and progressed to an almost complete loss of NF immunoreactivity at survival times of 1 year and longer. Immunohistochemistry for glial fibrillary acidic protein revealed a late astrocytic reaction starting at 4 months after injury in the degenerating tracts, leading to the long-term deposition of a dense astrocytic scar. These events were accompanied by the gradual reduction of myelin basic protein in affected nerve fibre tracts, leading to almost complete loss by 3 years after injury. Since the extracellular matrix molecule chondroitin sulphate proteoglycan (CSPG) is known to be strongly inhibitory for axonal regeneration and to be a major component of gliotic scar tissues, we investigated the possible deposition of CSPG within the degenerating nerve fibre tracts. Apart from a local up-regulation close to the lesion site, our results show no enhanced CSPG expression within degenerated tracts at any survival time. This suggests that despite the apparent lack of CSPG in Wallerian degeneration, the slow reduction of CNS myelin and the long-term deposition of a dense astrocytic scar may present an environment that is non-supportive for axon regrowth.
轴突在损伤点远端会发生沃勒变性。实验研究记录了许多构成这种现象基础的细胞和分子事件。由于对人类中枢神经系统病变中的此类事件了解相对较少,且当前的实验干预策略表明沿原始变性纤维束有显著轴突再生的可能性,我们对脑梗死或创伤性脊髓损伤后2天至30年死亡患者的尸检脊髓中沃勒变性的动态进行了免疫组织化学研究。神经丝(NF)染色显示,在变性的下行神经纤维束内,轴突损失呈现出时空模式,损伤后12天在病变附近即可检测到,在存活1年及更长时间时,NF免疫反应性几乎完全丧失。胶质纤维酸性蛋白免疫组织化学显示,损伤后4个月在变性束中开始出现晚期星形胶质细胞反应,导致致密星形胶质瘢痕的长期沉积。这些事件伴随着受影响神经纤维束中髓鞘碱性蛋白的逐渐减少,损伤后3年几乎完全丧失。由于细胞外基质分子硫酸软骨素蛋白聚糖(CSPG)已知对轴突再生具有强烈抑制作用,且是胶质瘢痕组织的主要成分,我们研究了CSPG在变性神经纤维束中的可能沉积情况。除了病变部位附近局部上调外,我们的结果显示在任何存活时间内,变性束内CSPG表达均未增强。这表明,尽管沃勒变性中明显缺乏CSPG,但中枢神经系统髓鞘的缓慢减少和致密星形胶质瘢痕的长期沉积可能会形成不利于轴突再生的环境。